CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing Strategy

Using AI, CDT Equity Inc. identifies a novel therapeutic indication for its lead programmes, supported by successful pre-clinical trial dataNAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 26, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announces that it has successfully identified a new biological target and novel therapeutic indication for its lead programme, AZD1656 (and its derivatives), following positive data from pre-clinical studies. This affirms the Company ...